Australia's most trusted
source of pharma news
Posted 16 January 2025 AM
Johnson & Johnson Innovative Medicine (Janssen) and Novartis remained the biggest PBS players during the financial year ending 2024, each earning $1 billion for a third consecutive year, according to the latest PBS Expenditure and Prescriptions Report.
The values given in the report are for Section 85 and Section 100 drugs, excluding Efficient Funding of Chemotherapy items, and including Doctors' Bag and under co-payment prescriptions. This means the current highest earner on the PBS, MSD's blockbuster cancer drug Keytruda is excluded from the list.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.